Aims/hypothesis The aim of this study was to investigate whether components of the renin-angiotensin system and semicarbazide-sensitive amine oxidase (SSAO) are associated with the development of pre-eclampsia in women with type 1 diabetes. without pre-eclampsia. Levels of renin, angiotensinogen and ACE did not differ in the two groups. Throughout pregnancy, prorenin and SSAO levels were 30% (p=0.004) and 16% (p=0.04) higher, respectively, in women developing pre-eclampsia. Using multivariate logistic regression analysis, prorenin concentration at 8 weeks was associated with pre-eclampsia .0], p=0.007), i.e. an increase of prorenin of 100 ng angiotensin I ml
Introduction
In women with type 1 diabetes, microalbuminuria and high blood pressure levels are risk factors for pre-eclampsia, but even diabetic women with normal blood pressure and normal urinary albumin excretion (UAE) are at risk of developing pre-eclampsia [1] . During the early stages of normal pregnancy, the renin-angiotensin system is activated with a tenfold increase in plasma prorenin levels at three to six gestational weeks, whereas much lower prorenin levels are detected from 9 weeks onwards, consistent with a role for the renin-angiotensin system in placentation and embryonic development [2] .
In pre-eclampsia, perturbation of the renin-angiotensin system is seen with increased vascular responsiveness to angiotensin II [3] . It is unknown whether other components of the renin-angiotensin system are affected in early pregnancy among women with type 1 diabetes who subsequently develop pre-eclampsia and whether this is affected by antihypertensive therapy.
Semicarbazide-sensitive amine oxidase (SSAO), an adhesion molecule present in blood vessels and plasma, is associated with endothelial cell cytotoxicity [4] and may be a marker of endothelial dysfunction and pre-eclampsia.
In this study, we investigated whether circulating concentrations of components of the renin-angiotensin system and of SSAO are associated with the development of pre-eclampsia in pregnant women with type 1 diabetes.
Methods
In a prospective observational study we consecutively included 107 Danish-speaking Europid women with type 1 diabetes referred to the Center for Pregnant Women with Diabetes, Rigshospitalet, before 14 completed gestational weeks with a single living fetus, from September 2004 to August 2006 [5] .
The research protocol was approved by the regional ethics committees.
Blood sampling was performed at medians of 8 (range 5-13), 14 (12-16), 21 (20-23), 27 (25-29) and 33 (31-35) weeks and once within 5 days postpartum [5] . Concentrations of prorenin and angiotensinogen and activity of renin, ACE and SSAO were analysed as previously described [5, 6] . Prorenin concentration was given as nanograms angiotensin I per millilitre per hour (ng AI ml
). For all assays, intra-and interassay CVs were below 10% [5, 6] .
Routine self-monitored plasma glucose (SMPG) was recommended at least seven times daily to obtain preprandial SMPG of 4.0-6.0 mmol/l, 90 min postprandial SMPG of 4.0-8.0 mmol/l, pre-bedtime SMPG of 6.0-8.0 mmol/l and HbA 1c ≤5.6%, in late pregnancy. Weight, HbA 1c , insulin dose and blood pressure were recorded at each clinical consultation at 1 or 2 week intervals throughout pregnancy [5] .
Presence of diabetic retinopathy at inclusion was routinely assessed by photo screening, which was evaluated by one experienced ophthalmologist [7] .
Based on 24 h UAE at inclusion, the women were classified as having normoalbuminuria (UAE <30 mg/24 h), microalbuminuria (UAE 30-299 mg/24 h) or diabetic nephropathy (UAE ≥300 mg/24 h). Pre-eclampsia in women with normoalbuminuria or microalbuminuria was defined as blood pressure >140/90 mmHg accompanied by proteinuria (≥1+) using a sterile urinary dip-stick (Uristix, Bayer Diagnostics, Bridgend, UK) or proteinuria ≥300 mg/24 h later than 20 weeks. In women with diabetic nephropathy, the diagnosis was based on the same findings accompanied by a sudden increase of ≥15% in systolic or diastolic blood pressure. Antihypertensive therapy was initiated if blood pressure ≥135/85 mmHg and/or UAE ≥300 mg/24 h [5] .
Statistical analyses Data are given as median (range) or numbers (%). Categorical variables were compared by χ 2 or Fisher's exact test, as appropriate. Continuous variables were analysed by parametric or non-parametric tests. Loglinear correlation analyses were performed using Pearson's coefficient, denoted r [5] .
To identify associations with pre-eclampsia, univariate logistic regression analysis was conducted with pre-eclampsia during pregnancy (yes/no) as dependent variable. Significant associations were further tested in backward stepwise multivariate logistic regression analysis. A variable remaining significant in this analysis was considered to be significantly associated with the development of pre-eclampsia. Statistically significant differences were defined as p<0.05.
Results
Pre-eclampsia developed in nine women (8%) at 34 (33-36) weeks (Table 1) . Throughout pregnancy, prorenin concentrations and SSAO activity remained 30% (p = 0.004) and 16% (p=0.04) higher, respectively, in women developing preeclampsia. No women with prorenin concentrations below 50.2 ng AI ml −1 h −1 or SSAO activity below 372 mU/l at inclusion developed pre-eclampsia (Table 1) . Prorenin concentrations decreased slightly and similarly from 8 weeks until postpartum in women with and without pre-eclampsia. Angiotensinogen concentrations and activity of renin and ACE were comparable between women with and without pre-eclampsia (p=0.79, p=0.43 and p=0.51, respectively, data not shown).
At inclusion, prorenin concentrations were positively correlated with duration of diabetes (r=0.33, p=0.0007).
Throughout pregnancy, activity of ACE and SSAO were positively correlated (r=0.32, p=0.001 at 8 weeks; r=0.38, p=0.0002 at 14 weeks; r=0.35, p=0.0005 at 21 weeks; r=0.37, p=0.0002 at 27 weeks; r=0.34, p=0.0007 at 33 weeks).
Eighty-two women remained normotensive without the need for antihypertensive therapy during pregnancy. In six women developing pre-eclampsia, antihypertensive therapy was initiated at a median of 31.5 weeks (range 14-36). Another four women without pre-eclampsia initiated antihypertensive therapy at 16.5 weeks (range 8-27) because of proteinuria or high blood pressure. One woman discontinued antihypertensive therapy at inclusion because of normal blood pressure and UAE. Among 14 women using antihypertensive therapy during the entire pregnancy, three women developed pre-eclampsia.
Among the six normotensive women with subsequent initiation of antihypertensive therapy and development of pre-eclampsia, prorenin concentrations at 8 weeks were higher (p= 0.03; Table 2 ), and throughout pregnancy prorenin concentrations remained 36% higher (p=0.001) compared with the 82 women remaining normotensive without antihypertensive therapy during pregnancy. No differences were detected in angiotensinogen concentrations (p=0.51) or in activity of renin, ACE or SSAO (p=0.57, p=0.96 and p=0.64, respectively).
Using 100 mg increase/24 h), systolic or diastolic blood pressure, presence of diabetic retinopathy, parity, concentration of angiotensinogen or activity of renin or ACE were not associated with development of pre-eclampsia. Using multivariate logistic regression analysis including prorenin concentrations at 8 weeks, SSAO activity at 8 weeks, UAE at 8 weeks (categorised as <30, 30-299 and ≥300 mg/24 h) and duration of diabetes, the only independent predictor of pre-eclampsia among all women was prorenin concentration at 8 weeks (OR 4.4 [95% CI 1.5-13.0], p = 0.007), i.e. an increase of prorenin of 100 ng AI ml −1 h −1 implies a 4.4 times higher risk of developing pre-eclampsia.
Discussion
In this observational study of 107 women with type 1 diabetes, high prorenin concentrations in early pregnancy predicted the development of pre-eclampsia in late pregnancy and, throughout pregnancy, prorenin concentrations remained 30% higher in women developing pre-eclampsia.
To exclude the possible influence of antihypertensive therapy on the components of the renin-angiotensin system and SSAO in early pregnancy, normotensive women without antihypertensive therapy in pregnancy were compared with normotensive women who were without antihypertensive therapy at inclusion and subsequently initiated antihypertensive therapy and developed preeclampsia. Despite the low number of women with preeclampsia in this analysis, a significant difference in prorenin concentrations was detected in early pregnancy compared with women without antihypertensive therapy during pregnancy, while baseline blood pressure and HbA 1c were comparable.
Throughout pregnancy, prorenin concentrations remained higher in all six women developing pre-eclampsia as compared with the 82 women remaining normotensive without antihypertensive therapy during pregnancy. This further indicates that high prorenin concentrations are associated with the development of pre-eclampsia in women with type 1 diabetes.
These findings are reminiscent of previous studies in non-pregnant participants showing that increased prorenin concentrations are present in diabetic individuals who subsequently develop microalbuminuria [8] . Pre-eclampsia is thought to be preceded by abnormal placentation, vascular development and trophoblast invasion in early pregnancy. Strongly increased angiotensin II type 1 (AT1) receptor levels have been found in non-diabetic women with pre-eclampsia [3] . In non-pregnant diabetic individuals with microvascular complications including microalbuminuria or diabetic nephropathy, changes in the renin-angiotensin system are seen, particularly in terms of increased plasma concentrations of prorenin being disproportionately increased compared with renin [8] . Likewise, microalbuminuria is known to be associated with the development of preeclampsia in women with type 1 diabetes [1] . We speculate that the changes in the renin-angiotensin system observed in the current study reflect maternal susceptibility present before pregnancy. SSAO activity was higher in early pregnancy and remained 16% higher throughout pregnancy in women with subsequent pre-eclampsia. Throughout pregnancy, SSAO was positively correlated with ACE activity in agreement with findings in non-pregnant type 1 diabetic individuals, suggesting an association between SSAO and the renin-angiotensin system [9] . Sikkema et al. [4] previously found no association between SSAO and preeclampsia, but in that study, SSAO activity was only assessed in late pregnancy in 14 non-diabetic women with pre-eclampsia and 14 healthy pregnant women.
According to our strategy of strict antihypertensive therapy [5] , antihypertensive therapy was given to 23% of the women. Although the number of women with preeclampsia in this observational study is too small for firm conclusions, a combined effect of improved glycaemic control and early intensive antihypertensive intervention may explain the lower proportion of women with preeclampsia as compared with previous reports of preeclampsia in approximately 13% of diabetic women [10] .
